Lead program: Discovery

Entheos Labs

Data updated June 27, 2026

1 Drug Candidate

Entheos Labs is a Boston-based psychedelic medicines company founded in 2022 by Dr. Jerry Rosenbaum and Tristan Edwards, dedicated to discovering, developing, and deploying novel psychedelic medicines for unmet medical needs. The company is creating a pipeline of new chemical entities derived from overlooked natural psychedelic materials, with its lead candidate ET-01 targeting mood, anxiety, trauma, and substance use disorders.

Pipeline Intelligence

Developer Momentum

Programme tracker

Active candidates: 1
Active programmes: 1
Lead stage: Discovery
Forecast coverage: 1 of 1

Latest sourced update

Psychedelic Alpha — Entheos Labs Coverage

Jun 27, 2026 - industry-media - Psychedelic Alpha - ET-01 (Synthetic Neuroplastogen)

Next known catalyst

preclinical-data

Timing not specified - ET-01 (Synthetic Neuroplastogen) / ET-01 — Preclinical Discovery - Confidence: 25%

4 sources0 pipeline-linked trials0 pipeline-linked papers

Development Programmes

ET-01 (Synthetic Neuroplastogen)

Discovery

Major Depressive Disorder (MDD)Treatment-Resistant Depression (TRD)Anxiety Disorders PTSD

ET-01 is a synthetic neuroplastogen derived from botanically sourced psychedelic compounds. Potent 5-HT2A receptor agonist designed to promote rapid structural neuroplasticity (dendritic spine growth, synaptogenesis) without requiring a full psychedelic experience. Discovered through Entheos's proprietary iPSC-based high-throughput screening platform that measures neuroplasticity directly in human neurons. The platform screens unscheduled psychedelic-adjacent plant-derived compounds — finding the "Goldilocks" zone of neuroplastic efficacy without hallucinatory or scheduling liabilities. Co-founder Jerry Rosenbaum (Harvard/MGH psychiatry chair emeritus) brings deep clinical trial design expertise. CSO Darrick Balu leads preclinical characterisation.

Programme Tracker

Major Depressive Disorder (MDD)

Primary: US (FDA)

DiscoveryActive

Forecast

preclinical-data

iPSC-based high-throughput neuroplasticity screening underway. ET-01 identified as lead from botanical compound library. Preclinical characterisation in progress — no IND filed, no ClinicalTrials.gov entries. Company is entirely in discovery/preclinical stage. $3.58M seed capital secured Sep 2024, SEC Form D filed Oct 2024 for up to $10M raise. Team building with world-class SAB: Robin Carhart-Harris, Adam Gazzaley, Sarah O'Connor.

Milestones

Company milestone

Completed

Actual: Jan 1, 2024

Entheos Labs founded by Jerry Rosenbaum (Harvard/MGH psychiatry chair emeritus) and A. Tristan Edwards (CEO). Focus on discovering non-psychedelic neuroplastogens from botanical sources using iPSC-based screening. Stephen Haggarty (MGH) serves as Chief Science Advisor.

Why it matters: Rosenbaum brings decades of Harvard psychiatry leadership and clinical trial expertise. Haggarty's MGH lab has pioneered iPSC-based psychiatric drug screening. Positions Entheos with elite academic credentials in a crowded neuroplastogen space.

Entheos Labs — Company Website(company-website)[Verified]

Funding milestone

Completed

Actual: Sep 17, 2024

$3.58M seed round closed. Investors: Lionheart Ventures, Satori Neuro, Conscience Capital, Possible Ventures, and additional angels. SEC Form D filed Oct 2024 indicating up to $10M total raise.

Why it matters: Seed funding enables iPSC screening platform buildout and preclinical characterisation of lead compounds. Investor base spans psychedelic-focused VCs (Satori Neuro, Conscience Capital) and broader biotech funds (Lionheart, Possible Ventures).

Entheos Labs SEC Form D Filing(Regulatory filing)[Verified]

Company milestone

Completed

Actual: Dec 1, 2024

Scientific Advisory Board assembled: Robin Carhart-Harris (UCSF, pioneered psilocybin neuroimaging), Adam Gazzaley (UCSF Neuroscape, digital therapeutics), Sarah O'Connor (Max Planck Institute, plant alkaloid biosynthesis). CSO: Darrick Balu (Harvard-trained neuroscientist).

Why it matters: Elite SAB combines psychedelic neuroscience leadership (Carhart-Harris), translational technology expertise (Gazzaley), and plant chemistry authority (O'Connor). Signals serious scientific credibility despite early stage.

Entheos Labs — Team & Advisors(company-website)[Verified]

Recorded Events

Dec 1, 2024: Company milestone

Sep 17, 2024: Funding milestone

Jan 1, 2024: Company milestone